Abdullah Elsayed is a Group Leader in Bispecific Antibody Research at Philochem AG, where they focus on developing next-generation bispecific antibodies for cancer immunotherapy. Abdullah holds a PhD in Pharmaceutical Sciences from ETH Zurich, where they specialized in antibody engineering, and has completed significant research in collaboration with Philochem AG. Prior to their doctorate, Abdullah gained experience in clinical development as a Clinical Scientist Intern at Novartis and served as a Biology Teacher and teaching assistant at various educational institutions. They are passionate about science communication, education, and fostering global perspectives through extracurricular programs centered on leadership and cultural exchange.
This person is not in the org chart
This person is not in any teams
This person is not in any offices